Ocrelizumab versus ofatumumab efficacy and safety after natalizumab discontinuation in multiple sclerosis: a retrospective real-world comparison.

Marino V, Moiola L, Zanetta C, Rubin M, Rossi L, Margoni M, Nozzolillo A, Gattuso I, Viti V, Petza E, et al.

J Neurol. 2026 Sep 08; 273(10). PMID: 42709219. Abstract